<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7958">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871429</url>
  </required_header>
  <id_info>
    <org_study_id>MEL080108</org_study_id>
    <nct_id>NCT00871429</nct_id>
  </id_info>
  <brief_title>Skin Care for Cancer Patients: A Product Satisfaction Survey</brief_title>
  <official_title>Selected Skin Products for Cancer Patients: A Product Satisfaction Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done because the investigators would like to evaluate product
      satisfaction of three test products (product A, product B, product C) that are available at
      any drug store. This will be done by measuring any changes in the subjects' answers to the
      Skindex-16 questionnaire at two time points (at screening and baseline visit and at
      follow-up visit) and by evaluating their responses to the product satisfaction survey that
      will be given to them by a study coordinator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate product satisfaction of the following
      test articles A, B, and C: Lindi Skin soothing balm (product A), Lindi Skin face serum
      (product B), and Lindi Skin face wash (product C). This will be done by measuring change in
      Skindex-16 questionnaire at two time points (baseline and follow-up visits) and by
      evaluating responses to the investigator administered product satisfaction survey.

      The secondary objective of this study is to see if there is any correlation between product
      satisfaction and grade of skin toxicity based on NCI-CTCAE v.3.0 scale.

      Participants in this study will be patients seen at the Northwestern University SERIES
      clinic or Lurie Cancer Center who are receiving chemotherapeutic and or radiation
      treatments. Subjects who choose to participate complete a Skindex16 questionnaire, and will
      after consenting to participate, be given all three test articles A, B, and C to use daily
      for one month. (These test articles are currently marketed products classified by the FDA as
      cosmetics).

      At the return visit, 1 month after baseline visit, the participant will be asked to return
      the test articles and complete an investigator administered product satisfaction
      questionnaire for each test article used. 100 participants will be surveyed. Subjects will
      be telephoned to check for product compliance after 1 week and 2 week intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</measure>
    <time_frame>one month of use</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Skin Toxicity Grades 0 to 5 Using The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 at Baseline Visit and 1 Month Follow-up After Using Lindi Products.</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Skin Toxicity</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lindi skin care products</intervention_name>
    <description>Subjects will then be instructed to apply all three products daily for 1 month.
The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C).</description>
    <other_name>Lindi Skin soothing balm (product A)</other_name>
    <other_name>Lindi Skin face serum (product B)</other_name>
    <other_name>Lindi Skin face wash (product C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are at least 18 years of age.

          -  Subjects who have the willingness and ability to understand and provide informed
             consent to participate in the study and are able to communicate with the
             investigator.

          -  Subjects who are seen in the SERIES clinic or Lurie Cancer Center and who are
             receiving chemotherapy and/or radiation treatment for malignancy

          -  Subjects who have grade &lt;2 skin toxicity based on NCI-CTCAE v3.0 scale.

          -  Subjects who are routine cosmetics users

        Exclusion Criteria:

          -  Under 18 years of age.

          -  Known allergy to any of the ingredients in the assigned products (Appendix C).

          -  Subjects who have grade 2,3,4 skin toxicity based on NCI-CTCAE v3.0 scale.

          -  Subjects who are pregnant, breast feeding, or those who are planning on becoming
             pregnant during test period.

          -  Subjects who use multiple topical agents on study areas
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario E Lacouture, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Haley AC, Calahan C, Gandhi M, West DP, Rademaker A, Lacouture ME. Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer. 2011 Apr;19(4):545-54. doi: 10.1007/s00520-010-0851-8. Epub 2010 Mar 25.</citation>
    <PMID>20336328</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 24, 2015</lastchanged_date>
  <firstreceived_date>March 26, 2009</firstreceived_date>
  <firstreceived_results_date>May 5, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Mario Lacouture MD</name_title>
    <organization>Northwestern University</organization>
  </responsible_party>
  <keyword>skin toxicity</keyword>
  <keyword>cancer patients</keyword>
  <keyword>adverse effects</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants in this study will be patients seen at the Northwestern University SERIES clinic or Lurie Cancer Center who are receiving chemotherapeutic and or radiation treatments.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lindi Skin Participant Flow</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Questionnaire not completed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cancer Patients Using Lindi Skin Products</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="94"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</title>
        <time_frame>one month of use</time_frame>
        <safety_issue>No</safety_issue>
        <population>the number of participants for analysis was determined per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Lindi Skin Soothing Balm (Product A)</title>
          </group>
          <group group_id="O2">
            <title>Lindi Skin Face Wash (Product C)</title>
          </group>
          <group group_id="O3">
            <title>Lindi Skin Face Serum (Product B)</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75"/>
                  <measurement group_id="O2" value="75"/>
                  <measurement group_id="O3" value="75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Product Satisfaction of the Following Test Articles A, B, and C: Lindi Skin Soothing Balm (Product A), Lindi Skin Face Serum (Product B), and Lindi Skin Face Wash (Product C)</title>
            <units>Percentage of Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Participant Product Satisfaction: Very Good/Good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.67"/>
                  <measurement group_id="O2" value="73.68"/>
                  <measurement group_id="O3" value="88.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participant Product Satisfaction: OK</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.00"/>
                  <measurement group_id="O2" value="23.68"/>
                  <measurement group_id="O3" value="9.09"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participant Product Satisfaction: Bad/Very Bad</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.33"/>
                  <measurement group_id="O2" value="2.63"/>
                  <measurement group_id="O3" value="2.60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Skin Toxicity Grades 0 to 5 Using The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 at Baseline Visit and 1 Month Follow-up After Using Lindi Products.</title>
        <time_frame>one month</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious and non-serious adverse events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lindi Skin Soothing Balm (Product A)</title>
        </group>
        <group group_id="E2">
          <title>Lindi Skin Face Wash (Product C)</title>
        </group>
        <group group_id="E3">
          <title>Lindi Skin Face Serum (Product B)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations of the trial identified.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mandy Browning</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-6829</phone>
      <email>mandybrowning2015@u.northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
